This study is testing an “investigational” compound called TP-1287. “Investigational” means that the Food and Drug Administration (FDA) has not yet approved this drug as a prescription medicine; it is only available through research studies like this. TP-1287 is a NEW, investigational product being developed by Tolero Pharmaceuticals as a therapy for advanced metastatic or progressive solid tumors. TP-1287 has been tested extensively in animals and in the laboratory, but this will be the first time that TP 1287 will be given to humans in a clinical trial. TP-1287 is a CDK9 inhibitor that blocks certain cancer cell growth functions which may lead to cancer cell death.
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
OPEN TO ACCRUAL